Universal Cells is a Seattle-based biotechnology company creating therapies using gene-modified pluripotent stem cells. By editing the genome of stem cells, the company can overcome the biggest challenge—rejection—associated with cellular therapies. By overcoming rejection, we enable allogeneic therapies, avoiding the complex logistics and high cost of goods of autologous therapies. The company has created Universal Donor Pluripotent Stem Cells which:
• Can be used without donor/recipient matching
• Can be expanded indefinitely
• Retain their ability to differentiate into multiple therapeutic cell types
• Can be rigorously tested to the highest possible quality standards.
Speaker: Bryan Steadman – Chief Technology Officer